Search Results - Anna Maria Langkilde

Refine Results
  1. 1
    Effects of high-resistant-starch banana flour (RS2) on in vitro fermentation and the small-bowel excretion of energy, nutrients, and sterols: an ileostomy study

    Effects of high-resistant-starch banana flour (RS2) on in vitro fermentation and the small-bowel excretion of energy, nutrients, and sterols: an ileostomy study by Anna Maria Langkilde, Martine Champ, Henrik Andersson

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Advances in dietary fibre characterisation. 1. Definition of dietary fibre, physiological relevance, health benefits and analytical aspects

    Advances in dietary fibre characterisation. 1. Definition of dietary fibre, physiological relevance, health benefits and analytical aspects by Martine Champ, Anna-Maria Langkilde, Fred Brouns, Bernd Kettlitz, Yves Le Bail Collet

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Advances in dietary fibre characterisation. 2. Consumption, chemistry, physiology and measurement of resistant starch; implications for health and food labelling

    Advances in dietary fibre characterisation. 2. Consumption, chemistry, physiology and measurement of resistant starch; implications for health and food labelling by Martine Champ, Anna-Maria Langkilde, Fred Brouns, Bernd Kettlitz, Yves Le Bail-Collet

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial

    Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Pl... by Krzysztof Strojek, Kun‐Ho Yoon, Veronika Hrubá, Jennifer Sugg, Anna Maria Langkilde, Shamik Parikh

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

    Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials by Serge Jabbour, Jochen Seufert, André Scheen, Clifford J. Bailey, Cathrina Karup, Anna Maria Langkilde

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

    Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metf... by Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

    Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study by Kohei Kaku, Hiroshi Maegawa, Yukio Tanizawa, Arihiro Kiyosue, Yumiko Ide, Takuto Tokudome, Yuji Hoshino, Yang JISIN, Anna Maria Langkilde

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2

    Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2 by Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis

    Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis by Geoffrey A. Block, David P. Rosenbaum, Maria Leonsson‐Zachrisson, Magnus Åstrand, Susanne Johansson, Mikael Knutsson, Anna Maria Langkilde, Glenn M. Chertow

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

    Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study by Paola Fioretto, Stefano Del Prato, John B. Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C. David Sjöström, Peter Sartipy

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

    Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diab... by Carol A. Pollock, Bergur V. Stefánsson, Daniel Reyner, Peter Rossing, C. David Sjöström, David C. Wheeler, Anna Maria Langkilde, Hiddo J.L. Heerspink

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... by Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol A. Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction

    Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction by Stefan James, David Erlinge, Robert F. Storey, Darren K. McGuire, Mark de Belder, Ida Björkgren, Peter A. Johansson, Anna Maria Langkilde, Wilhelm Ridderstråle, Ehsan Parvaresh Rizi, John Deanfield, Jonas Oldgren

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

    A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular... by John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Anna Maria Langkilde, Felipe A. Martínez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabatine, Mikaela Sjöstrand, Scott D. Solomon

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics

    The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics by John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Anna Maria Langkilde, Felipe A. Martínez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabatine, Mikaela Sjöstrand, Scott D. Solomon

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial

    Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial by Glenn M. Chertow, Ricardo Correa‐Rotter, Priya Vart, Niels Jongs, John J.V. McMurray, Peter Rossing, Anna Maria Langkilde, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Effects of <b>da</b>pagliflozin on prevention of major clinical events and recovery in patients with <b>re</b>spiratory failure because of COVID‐<b>19</b>: Design and rationale for the DARE‐19 study

    Effects of <b>da</b>pagliflozin on prevention of major clinical events and recovery in patients with <b>re</b>spiratory failure because of COVID‐<b>19</b>: Design and rationale for... by Mikhail Kosiborod, Otávio Berwanger, Gary G. Koch, Felipe A. Martínez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Ali Javaheri, Philip Ambery, Samvel B. Gasparyan, Joan Buenconsejo, C. David Sjöström, Anna Maria Langkilde, Jan Oscarsson, Russell Esterline

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty

    Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty by Priya Vart, Jawad H. Butt, Niels Jongs, Meir Schechter, Glenn M. Chertow, David C. Wheeler, Roberto Pecoits–Filho, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, John J.V. McMurray, Hiddo J.L. Heerspink

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CK... by Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Tom Greene

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial by Niels Jongs, Tom Greene, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: